The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...

The latest findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) reveal that patients with germline BRCA ...

Nektar Therapeutics announced promising results from a Phase 2 study of its experimental drug NKTR-255, which improved ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...

The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...

General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven ...

The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...

Roche has announced a definitive agreement to acquire Poseida Therapeutics, a clinical-stage biopharmaceutical company ...

FDA has granted accelerated approval to Bizengri® (zenocutuzumab-zbco), a first-in-class bispecific antibody targeting NRG1+ ...

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves three-year disease-free survival (96%) in children ...